Idorsia Pharmaceuticals Ltd: Clear route to registration positions lucerastat as the potential first oral therapy for all patients with Fabry disease

Allschwil, Switzerland - February 06, 2026Idorsia Ltd (SIX: IDIA) announces the design of its FDA-agreed Phase 3 registration program for lucerastat in Fabry disease. Building on the robust biomarker ...
Kauppalehti

Clear route to registration positions lucerastat as the potential first oral therapy for all patients with Fabry disease

Designed to reinforce lucerastat as the first oral therapy suitable for all patients with Fabry disease, irrespective of their mutation type. The program is expected to support a potential regulatory ...
Cochrane

What are the benefits and risks of surgery for women with pelvic organ prolapse, with or without incontinence?

- In women with pelvic organ prolapse (POP) and stress urinary incontinence (SUI), continence surgery at the same time as POP surgery likely improves rates of SUI after surgery. In continent women ...

Denali Therapeutics Inc. (DNLI) Shareholder/Analyst Call Transcript

Shareholder/Analyst Call February 5, 2026 3:30 PM ESTCompany ParticipantsRyan Watts - Co-Founder, President, CEO ...